Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-5,page-paged-5,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress
    21 November 2022
    www.marinomed.com
  • ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology; Company also Wins First Place in 2022 Brain-Computer Interface Awards
    21 November 2022
    www.onwd.com
  • After seven years of accelerated growth at Rentschler Biopharma SE under his leadership as CEO, Dr. Frank Mathias to return to the Supervisory Board
    21 November 2022
    www.rentschler-biopharma.com
  • Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality
    16 November 2022
    www.element.com
  • Lindis Blood Care Establishes Scientific Advisory Board of Leading Industry Experts
    16 November 2022
    www.lindis-bloodcare.com
  • Rentschler Biopharma appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board
    16 November 2022
    www.rentschler-biopharma.com
  • ABIVAX RELEASES THE RESULTS OF ITS NOVEMBER 9, 2022 AD HOC ORDINARY AND EXTRAORDINARY GENERAL MEETING
    15 November 2022
    www.abivax.com
  • Destiny Pharma: XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
    15 November 2022
    www.destinypharma.com
  • Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
    15 November 2022
    www.mainzbiomed.com
  • LINDIS Biotech Presented Encouraging Data from High Risk-Non-Muscle-Invasive Bladder Cancer Patients Treated with Trifunctional Antibody CATUMAXOMAB at EMUC22
    14 November 2022
    www.lindisbiotech.com